Healthcare -
Drug Manufacturers - General - NASDAQ - FR
$ 52.27
-2.64 %
$ 129 B
Market Cap
22.05
P/E
1. INTRINSIC VALUE
Balance Sheet
Sanofi
| Current Assets | 42.6 B |
| Cash & Short-Term Investments | 7.93 B |
| Receivables | 10.6 B |
| Other Current Assets | 24 B |
| Non-Current Assets | 90.2 B |
| Long-Term Investments | 3.26 B |
| PP&E | 11.6 B |
| Other Non-Current Assets | 75.4 B |
| Current Liabilities | 29.2 B |
| Accounts Payable | 7.55 B |
| Short-Term Debt | 4.47 B |
| Other Current Liabilities | 17.1 B |
| Non-Current Liabilities | 25.8 B |
| Long-Term Debt | 13.4 B |
| Other Non-Current Liabilities | 12.3 B |
EFFICIENCY
Earnings Waterfall
Sanofi
| Revenue | 44.3 B |
| Cost Of Revenue | 13.2 B |
| Gross Profit | 31.1 B |
| Operating Expenses | 23.8 B |
| Operating Income | 7.25 B |
| Other Expenses | 1.76 B |
| Net Income | 5.5 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Sanofi
| Net Income | 5.5 B |
| Depreciation & Amortization | 3.59 B |
| Capital Expenditures | -3.2 B |
| Stock-Based Compensation | 0 |
| Change in Working Capital | -615 M |
| Others | 517 M |
| Free Cash Flow | 5.89 B |
Wall Street Analysts Price Targets
Sanofi
Wall Street analysts predict an average 1-year price target for SNY of $58.5 , with forecasts ranging from
a
low of
$48.1 to a high of $64 .
SNY Lowest Price Target
Wall Street Target
48.1 USD
-8.04%
SNY Average Price Target
Wall Street Target
58.5 USD
11.94%
SNY Highest Price Target
Wall Street Target
64 USD
22.44%
4. DIVIDEND
ANALYSIS
0.00%
DIVIDEND YIELD
1.61 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Sanofi
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Sanofi: Investing in prevention builds Europe's health and competitiveness
WARSAW, Poland, May 06, 2025 (GLOBE NEWSWIRE) -- As the Polish Presidency of the EU Council enters its final stage health policy remains central to Europe's strategic agenda. At the European Economic Congress in Katowice, discussions reflected both the Presidency's efforts to strengthen healthcare resilience and drive digital transformation, and a broader consensus that prevention, innovation, and life science leadership must be at the core of Europe's long-term strategy. Sanofi's experts highlighted the pivotal role of immunization, respiratory health, and sustainable innovation in building a healthier and competitive Europe.
globenewswire.com
- 2 weeks ago
Press Release: Annual General Meeting of April 30, 2025
Annual General Meeting of April 30, 2025 Approval of the financial statements for the fiscal year 2024 Distribution of a cash dividend of €3.92 per share, with payment as of May 14, 2025 Board composition: renewal of four Directors and ratification of the cooptation of Jean-Paul Kress Paris, April 30, 2025. The Combined General Shareholders' Meeting of Sanofi was held on April 30, 2025, under the chairmanship of Frédéric Oudéa.
globenewswire.com
- 2 weeks ago
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
Sanofi and CD&R close Opella transaction, creat e global consumer healthcare leader Paris, April 30, 2025 . Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in Sanofi's strategy.
globenewswire.com
- 2 weeks ago
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
globenewswire.com
- 3 weeks ago
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race
globenewswire.com
- 3 weeks ago
Sanofi (SNY) Q1 2025 Earnings Call Transcript
Sanofi (NASDAQ:SNY ) Q4 2024 Earnings Call Transcript Q1 2025 Earnings Conference Call April 25, 2025 7:00 AM ET Company Participants Thomas Kudsk Larsen - Head, Investor Relations Paul Hudson - Chief Executive Officer François Roger - Executive Vice President, Chief Financial Officer Houman Ashrafian - Executive Vice President, Head of Research & Development Thomas Triomphe - Executive Vice President, Vaccines Brian Foard - Executive Vice President, Head of Specialty Care Conference Call Participants Richard Vosser - JPMorgan Luisa Hector - Berenberg Colleen Garvey - Guggenheim Ben Jackson - Jefferies Peter Verdult - BNP Exane Jo Walton - UBS Graham Parry - BofA James Quigley - Goldman Sachs Florent Cespedes - Bernstein Sarita Kapila - Morgan Stanley Simon Baker - Redburn Thomas Kudsk Larsen Hello everyone. This is Thomas Kudsk Larsen from the Sanofi IR team.
seekingalpha.com
- 3 weeks ago
Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth
SNY beats Q1 estimates for earnings, while missing the same for sales. It expects earnings growth to rebound in 2025.
zacks.com
- 3 weeks ago
Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug
The pharmaceutical company said the profit was driven by a higher gross margin and slower operating expense growth.
wsj.com
- 3 weeks ago
Innate Pharma Announces €15M Investment by Sanofi
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announces a €14,999,998.59 capital increase subscribed by Sanofi. As announced on April 23, 2025, and given the satisfactory market conditions, Sanofi has agreed to subscribe to 8,345,387 new ordinary shares of Innate, at a price of €1.7974 per share, representing a total capital increase of €14,999,998.59 (€417,269.35 in nominal amount and €14,582,729.24 o.
businesswire.com
- 3 weeks ago
Sanofi's quarterly profit beats estimates on Dupixent boost, newer products
France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its anti-inflammatory drug Dupixent, as well as newer treatments and vaccines.
reuters.com
- 3 weeks ago
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER 1 and business EPS 2 of €1.79 Pharma launches reached sales of €0.8 billion, up 43.8%, driven by ALTUVIIIO Dupixent sales were €3.5 billion, up 20.3% Vaccines sales were €1.3 billion, up 11.4%, driven by favorable Beyfortus phasing Research and Development expenses reached €1.8 billion, up 6.9% Selling, general and administrative expenses were €2.2 billion, up 3.8% Business EPS was €1.79, up 15.7% at CER and up 17.0% reported; IFRS EPS was €1.52 Pipeline continued to deliver Six regulatory approvals across medicines in immunology, rare diseases, and oncology Recent new data from the mid-stage pipeline unlocks late-stage studies in asthma and skin diseases, broadening and deepening the scope in immunology Sustainability strategy Updated sustainability strategy focuses on access to healthcare, environmental impact, and resilience of healthcare systems. 70% of the portfolio and >75% of the pipeline target diseases that are impacted by climate and environmental challenges Capital allocation The closing of the sale of a controlling stake in Opella to CD&R is anticipated in Q23 Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager4 Guidance confirmed In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER5.
globenewswire.com
- 3 weeks ago
Novartis and Sanofi CEOs say EU should raise drug prices in face of tariffs
The European Union should allow drug prices to rise to U.S. levels in order to attract investment, the bosses of two European pharmaceutical giants said in a letter published in the Financial Times on Wednesday.
reuters.com
- 3 weeks ago
8. Profile
Summary
Sanofi SNY
COUNTRY
FR
INDUSTRY
Drug Manufacturers - General
MARKET CAP
$ 129 B
Dividend Yield
0.00%
Description
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Contact
54, Rue La BoEtie, Paris, 75008
https://www.sanofi.com
IPO
Date
July 1, 2002
Employees
82878
Officers
Mr. Paul Hudson
Chief Executive Officer & Director
Mr. Laurent Gilhodes
Principal Accounting Officer and Vice President of Corporate Accounting
Mr. Pierre Chancel
Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing
Mr. Thomas Kudsk Larsen
Head of Investor Relations
Mr. Roy Papatheodorou
Executive Vice President & General Counsel
Ms. Madeleine Roach
Executive Vice President & Head of Business Operations
Dr. Josephine Fubara
Chief Science Officer of Consumer Health Care
Ms. Natalie Bickford
Executive Vice President & Chief People Officer
Mr. Dante Beccaria
Global Compliance Officer & Vice President
Mr. François-Xavier Roger
Executive Vice President & Chief Financial Officer